0,31 USD-2,4%zamknięcie 13 lis
The latest quarter (ended 30 września 2026) is from EyePoint’s earnings press release of 12 listopada 2026. It will be replaced by the official quarterly report (10-Q) once EyePoint files it.
| Miara | 3 miesiące do30 wrz 2026 | 3 miesiące do30 wrz 2025 | Zmiana |
|---|---|---|---|
| Przychody ogółem | 756K USD | 966K USD | -21,74% |
| Zysk | -95,6M USD | -59,7M USD | -60,07% |
To pojedyncze kwartały, a nie rok kroczący — liczby w innych miejscach serwisu obejmują dwanaście miesięcy i będą znacznie większe. Biznes sezonowy waha się między nimi mocno: ServiceNow generuje 2,0 mld $ wolnych przepływów w kwartale grudniowym i 0,5 mld $ w czerwcowym.
Porównane z tym samym kwartałem rok wcześniej, a nie z prognozą analityków. „Beat” albo „miss” wymaga konsensusu, czyli danych licencjonowanych, których nie mamy — a pomyłka jest gorsza niż pominięcie.
“The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing. This important data supports our strategic decision to prioritize our resources on DME, where we believe there is strong scientific and clinical rationale for DURAVYU as a durable treatment option for this vision threatening exudative disease.”
Cytowane dosłownie z komunikatu i pokazywane tylko wtedy, gdy raport przypisuje wypowiedź konkretnej osobie.
Komunikaty pojawiają się przed otwarciem albo po zamknięciu, więc okno biegnie od zamknięcia przed dniem raportu do zamknięcia sesji po nim — reakcja mieści się w nim w obu przypadkach.
Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME). The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation. EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan. DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Własny opis spółki, tak jak widnieje na końcu komunikatu.
The quote, the company description and the latest quarter come from EyePoint’s earnings press release (an Item 2.02 8-K) filed 12 listopada 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Przeczytaj komunikat w EDGAR Kursy są skorygowane o splity i dywidendy.
EyePoint, Inc. reported on 12 listopada 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From EyePoint, Inc.'s results release of 12 listopada 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
756K USD
-22% y/y
+49% q/q
Guided
—
No guide given
Actual
-96,9M USD
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.